PBM Rules Are Pivotal Point Of Medicare Rx Debate, Breaux Tells PhRMA
Executive Summary
The structure of competition among PBMs is a key point for industry to weigh in on during the Medicare drug benefit debate, Sen. Breaux (D-La.) told the Pharmaceutical Research & Manufacturers of America annual meeting March 31 in Naples, Fla.
You may also be interested in...
PhRMA Staff Expansion May Help With New Medicare Rx Broker Baucus
PhRMA's federal affairs staff expansion includes a timely addition that should help the trade association work with incoming Finance Committee Chairman Baucus (D-Mont.).
PhRMA Staff Expansion May Help With New Medicare Rx Broker Baucus
PhRMA's federal affairs staff expansion includes a timely addition that should help the trade association work with incoming Finance Committee Chairman Baucus (D-Mont.).
Kennedy PhRMA-Friendly Agenda Includes Wariness Of Waxman/Hatch Reform
Waxman/Hatch reform should not be undertaken without setting clear boundaries, Sen. Kennedy (D-Mass.) told the Pharmaceutical Research & Manufacturers of America annual meeting in Naples, Fla., March 31.